GB9930616D0 - Activation and inhibition of the immune system - Google Patents
Activation and inhibition of the immune systemInfo
- Publication number
- GB9930616D0 GB9930616D0 GBGB9930616.9A GB9930616A GB9930616D0 GB 9930616 D0 GB9930616 D0 GB 9930616D0 GB 9930616 A GB9930616 A GB 9930616A GB 9930616 D0 GB9930616 D0 GB 9930616D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- inhibition
- inhibitors
- activation
- immune system
- iob
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/06—Uses of viruses as vector in vitro
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930616.9A GB9930616D0 (en) | 1999-12-24 | 1999-12-24 | Activation and inhibition of the immune system |
| NZ519438A NZ519438A (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
| EP00985660A EP1244466B1 (en) | 1999-12-24 | 2000-12-22 | ACTIVATION OF THE IMMUNE SYSTEM BY AN NF-kappaB INDUCER AND AN ANTIGEN |
| EP07014428A EP1852123A3 (en) | 1999-12-24 | 2000-12-22 | Inhibition of the immune system by inhibitors of NF-kappaB |
| PCT/GB2000/004925 WO2001047543A2 (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
| ES00985660T ES2302707T3 (es) | 1999-12-24 | 2000-12-22 | Activacion del sistema inmunitario por un inductor nf-kappa b y un antigeno. |
| DE60038503T DE60038503T2 (de) | 1999-12-24 | 2000-12-22 | AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER |
| US10/168,805 US7915009B2 (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
| CA002394880A CA2394880A1 (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
| CNB200610051522XA CN100563707C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
| JP2001548135A JP2003518507A (ja) | 1999-12-24 | 2000-12-22 | 免疫系の活性化および阻害 |
| AT00985660T ATE390929T1 (de) | 1999-12-24 | 2000-12-22 | Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser |
| AU22062/01A AU781496B2 (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
| CNB008191050A CN1254272C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
| US11/987,956 US20080124322A1 (en) | 1999-12-24 | 2007-12-06 | Activation and inhibition of the immune system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930616.9A GB9930616D0 (en) | 1999-12-24 | 1999-12-24 | Activation and inhibition of the immune system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB9930616D0 true GB9930616D0 (en) | 2000-02-16 |
Family
ID=10867023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9930616.9A Ceased GB9930616D0 (en) | 1999-12-24 | 1999-12-24 | Activation and inhibition of the immune system |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7915009B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1852123A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003518507A (cg-RX-API-DMAC7.html) |
| CN (2) | CN1254272C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE390929T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU781496B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2394880A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60038503T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2302707T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB9930616D0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ519438A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001047543A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| EP1345617A2 (en) * | 2000-12-22 | 2003-09-24 | Synovis Limited | Methods of modulating toll-related receptor (trr) signaling |
| GB0116249D0 (en) * | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
| JP2003055202A (ja) * | 2001-08-15 | 2003-02-26 | Hiroyuki Hanai | 炎症性腸疾患の予防・治療剤 |
| CN1306964C (zh) * | 2002-05-29 | 2007-03-28 | 安琪士摩奇株式会社 | 治疗和预防炎症性疾病的诱饵组合物 |
| AU2002953094A0 (en) * | 2002-12-04 | 2002-12-19 | The University Of Queensland | Immunomodulating compositions, processes for their production and uses therefor |
| WO2004027063A1 (en) * | 2002-09-19 | 2004-04-01 | Institut National De La Sante Et De La Recherche Medicale-Inserm | Use of sirnas for gene silencing in antigen presenting cells |
| CA2516320C (en) * | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| US20050147608A1 (en) * | 2003-05-08 | 2005-07-07 | Beth Israel Deaconess Medical Center, Inc. | Novel regulatory mechanisms of NF-kappaB |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
| KR20080052549A (ko) * | 2005-06-23 | 2008-06-11 | 베이롤 칼리지 오브 메드신 | 네거티브 면역 조절인자의 조절 및 면역요법을 위한 적용 |
| CA2623153A1 (en) * | 2005-09-20 | 2007-03-29 | London Health Sciences Centre Research Inc. | The use of sirnas in organ storage/reperfusion solutions |
| ES2435775T3 (es) | 2005-10-27 | 2013-12-23 | Janssen Biotech, Inc. | Moduladores de receptor tipo Toll 3, procedimientos y usos |
| CN102851295B (zh) * | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| CA2702340C (en) * | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
| US8691210B2 (en) * | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| WO2008080195A1 (en) * | 2006-12-29 | 2008-07-10 | The University Of Queensland | Compositions and methods for treating or preventing unwanted immune responses |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| JP6313203B2 (ja) * | 2011-07-18 | 2018-04-18 | ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションUniversity Of Kentucky Research Foundation | Alu−rna誘導変性からの細胞の保護及び細胞保護用阻害剤 |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| EP3043641B1 (en) * | 2013-09-12 | 2019-09-11 | Icahn School of Medicine at Mount Sinai | Methods of making transgenic animals with t cell receptors that are specific to a flourescent protein |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| US20150342961A1 (en) * | 2014-06-03 | 2015-12-03 | Hai-Hui Xue | Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml) |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| WO2016071758A1 (en) | 2014-11-03 | 2016-05-12 | Leiden University Medical Center | T cell receptors directed against bob1 and uses thereof |
| WO2016094679A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US10420836B2 (en) | 2015-10-08 | 2019-09-24 | Emory University | Methods of immunizing a subject and compositions related thereto |
| CR20210587A (es) | 2019-05-31 | 2022-02-11 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5149796A (en) | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| EP0500785B1 (en) | 1989-11-03 | 2002-04-17 | Immulogic Pharmaceutical Corporation | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| CA2105595A1 (en) * | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
| US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
| US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
| DK0759944T3 (da) | 1994-05-13 | 2001-11-26 | Biovation Ltd | Forbedringer af og relateret til peptidfremføring |
| WO1996003144A1 (en) | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
| US5597898A (en) | 1995-02-15 | 1997-01-28 | Yale University | NF-κB activation regulatory protein, IκB-β |
| WO1997001340A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal mast cell stabilizers |
| EP0779361A3 (en) | 1995-12-15 | 1999-11-10 | F. Hoffmann-La Roche Ag | Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof |
| UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| FI990180A7 (fi) * | 1996-08-12 | 1999-03-08 | Celgene Corp | Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi |
| CA2263835C (en) * | 1996-08-26 | 2012-02-21 | Signal Pharmaceuticals, Inc. | Stimulus-inducible i (kappa)b kinase [ikk] signalsome |
| US5891924A (en) * | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
| ATE497001T1 (de) * | 1996-12-23 | 2011-02-15 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| US6924308B1 (en) | 1997-07-30 | 2005-08-02 | Howard L. Elford | Therapeutic process for inhibiting NF-κB |
| US5952483A (en) | 1997-07-31 | 1999-09-14 | Smithkline Beecham Corporation | Human IκB-β |
| EP0897009A3 (en) | 1997-08-04 | 1999-06-09 | Smithkline Beecham Plc | HKABY60 polypeptides |
| JPH1171278A (ja) * | 1997-09-01 | 1999-03-16 | Kanegafuchi Chem Ind Co Ltd | 転写因子NF−κB活性化阻害剤 |
| GB9719238D0 (en) | 1997-09-11 | 1997-11-12 | Mathilda & Terence Kennedy Ins | Viral infection of cells |
| US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US5965421A (en) | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| WO1999042137A2 (en) | 1998-02-19 | 1999-08-26 | Peter Bromley | Stress promoter control of therapeutic genes in gene therapy: compositions and methods |
| ATE309352T1 (de) * | 1998-05-06 | 2005-11-15 | Vlaams Interuniv Inst Biotech | Inhibitoren der nf-kb aktivierung |
| HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| EP1165144A2 (en) * | 1999-03-15 | 2002-01-02 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| EP1345617A2 (en) | 2000-12-22 | 2003-09-24 | Synovis Limited | Methods of modulating toll-related receptor (trr) signaling |
| GB0116249D0 (en) | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
-
1999
- 1999-12-24 GB GBGB9930616.9A patent/GB9930616D0/en not_active Ceased
-
2000
- 2000-12-22 CN CNB008191050A patent/CN1254272C/zh not_active Expired - Fee Related
- 2000-12-22 WO PCT/GB2000/004925 patent/WO2001047543A2/en not_active Ceased
- 2000-12-22 NZ NZ519438A patent/NZ519438A/en not_active IP Right Cessation
- 2000-12-22 CA CA002394880A patent/CA2394880A1/en not_active Abandoned
- 2000-12-22 AT AT00985660T patent/ATE390929T1/de not_active IP Right Cessation
- 2000-12-22 EP EP07014428A patent/EP1852123A3/en not_active Withdrawn
- 2000-12-22 AU AU22062/01A patent/AU781496B2/en not_active Ceased
- 2000-12-22 US US10/168,805 patent/US7915009B2/en not_active Expired - Fee Related
- 2000-12-22 ES ES00985660T patent/ES2302707T3/es not_active Expired - Lifetime
- 2000-12-22 JP JP2001548135A patent/JP2003518507A/ja active Pending
- 2000-12-22 CN CNB200610051522XA patent/CN100563707C/zh not_active Expired - Fee Related
- 2000-12-22 DE DE60038503T patent/DE60038503T2/de not_active Expired - Lifetime
- 2000-12-22 EP EP00985660A patent/EP1244466B1/en not_active Expired - Lifetime
-
2007
- 2007-12-06 US US11/987,956 patent/US20080124322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1254272C (zh) | 2006-05-03 |
| US7915009B2 (en) | 2011-03-29 |
| EP1852123A3 (en) | 2008-09-10 |
| US20080124322A1 (en) | 2008-05-29 |
| CA2394880A1 (en) | 2001-07-05 |
| JP2003518507A (ja) | 2003-06-10 |
| WO2001047543A3 (en) | 2002-01-17 |
| CN100563707C (zh) | 2009-12-02 |
| CN1817367A (zh) | 2006-08-16 |
| EP1244466B1 (en) | 2008-04-02 |
| DE60038503D1 (de) | 2008-05-15 |
| US20030153518A1 (en) | 2003-08-14 |
| CN1434718A (zh) | 2003-08-06 |
| ATE390929T1 (de) | 2008-04-15 |
| AU2206201A (en) | 2001-07-09 |
| WO2001047543A2 (en) | 2001-07-05 |
| EP1244466A2 (en) | 2002-10-02 |
| DE60038503T2 (de) | 2009-04-30 |
| EP1852123A2 (en) | 2007-11-07 |
| NZ519438A (en) | 2004-03-26 |
| ES2302707T3 (es) | 2008-08-01 |
| AU781496B2 (en) | 2005-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60038503D1 (de) | AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER | |
| AU4932199A (en) | Cancer antigens based on tumor suppressor gene wt1 product | |
| AU5584999A (en) | System for the rapid manipulation of nucleic acid sequences | |
| YU84303A (sh) | Postupak dobijanja cetp inhibitora | |
| WO2001018248A3 (en) | Quorum sensing signaling in bacteria | |
| EP0871767A4 (en) | METHOD FOR AMPLIFYING SPECIFIC NUCLEIC ACID SEQUENCES | |
| AU6114700A (en) | Novel system for the sequential, directional cloning of multiple dna sequences | |
| WO2000049158A3 (en) | Psa and klk-2 splicing variants | |
| MXPA01008605A (es) | Proteina de enlace del antigeno goodpasture. | |
| WO2000009693A3 (en) | Identification of the gene causing the mouse scurfy phenotype and its human ortholog | |
| AU6724794A (en) | GRB3-3 gene, its variants and their uses | |
| EP0601585A3 (en) | Nucleic acid construct for inhibiting or regulating the functions of an immune response gene, its use in a method and immunocompatible system containing this construct. | |
| ZA97835B (en) | Purified sr-p70 protein | |
| WO2001088124A3 (en) | Method and reagent for the inhibition of erg | |
| AU4300497A (en) | Process for the manufacture of aliphatic alpha, omega amino nitriles | |
| ZA989705B (en) | Epoxide hydrolase | |
| BG103319A (en) | Method for the preparation of hydroxamic acids | |
| WO2003025134A3 (en) | mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF | |
| WO2002083727A3 (de) | Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse | |
| WO1999055874A3 (en) | Nucleic acids of the m antigen gene of histoplasma capsulatum, antigens, vaccines and antibodies, methods and kits for detecting histoplasmosis | |
| WO2002036780A3 (en) | Stearoyl-coa desaturase gene promoter | |
| WO2002046378A3 (en) | Alternative pol k nucleotide and amino acid sequence and methods for using | |
| MX9204348A (es) | Vector de adn para la transformacion de celulas de bacillus thuringiensis. | |
| AU4496196A (en) | Recombinant DNA comprising DNA coding for myosin heavy chain SM1 isoform protein inserted into vector DNA, microorganism carrying the recombinant DNA, and an agent for treatment of arteriosclerosis comprising the recombinant DNA | |
| EP1174503A4 (en) | NOVEL PROTEINS, GENES ENCODING THEM AND METHODS OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |